Literature DB >> 26704278

[Systemic cancer treatment in geriatric patients].

J Hess1.   

Abstract

BACKGROUND: Functional health issues and the ability to autonomously participate in social life play a more pronounced role for geriatric patients than the mere prolongation of life. Quality-adjusted life years reflect the relation of health and life span. Comorbidities and functional or cognitive impairment represent independent predictors for the overall survival of geriatric patients. This must be kept in mind when planning systemic cancer treatment. THERAPY: All forms of cancer-specific therapy should evaluate whether the patient can truly benefit taking into consideration geriatric aspects. This particularly demands a great deal of palliative chemotherapy. When curation is no longer possible, a cancer-specific treatment must not lead to therapy-related symptoms. Clear communication of the aims of therapy is indispensable. In addition to routine urooncologic data, other relevant information must be inquired in advance of cancer-specific treatment in order to identify those functionally or cognitively impaired patients who may not benefit from systemic cancer treatment.
CONCLUSION: A precise indication with respect of age-dependent physiological changes and a clear prioritization of symptoms outline the approach for systemic cancer-specific treatment.

Entities:  

Keywords:  Androgen deprivation; Chemotherapy; Demografic change; Immunotherapy; Oncology

Mesh:

Substances:

Year:  2015        PMID: 26704278     DOI: 10.1007/s00120-015-4009-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  41 in total

Review 1.  Psychosocial correlates of cancer relapse and survival: a literature review.

Authors:  M F De Boer; R M Ryckman; J F Pruyn; H W Van den Borne
Journal:  Patient Educ Couns       Date:  1999-07

2.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

3.  Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.

Authors:  Paul L Nguyen; Ming-Hui Chen; Joshua A Beckman; Clair J Beard; Neil E Martin; Toni K Choueiri; Jim C Hu; Karen E Hoffman; Daniel E Dosoretz; Brian J Moran; Sharon A Salenius; Michelle H Braccioforte; Philip W Kantoff; Anthony V D'Amico; Ronald D Ennis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-25       Impact factor: 7.038

Review 4.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Authors:  Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora N Sternberg; Dean F Bajorin; Joaquim Bellmunt
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  EORTC elderly task force position paper: approach to the older cancer patient.

Authors:  A G Pallis; C Fortpied; U Wedding; M C Van Nes; B Penninckx; A Ring; D Lacombe; S Monfardini; P Scalliet; H Wildiers
Journal:  Eur J Cancer       Date:  2010-03-12       Impact factor: 9.162

6.  Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.

Authors:  Matthew D Galsky; Susan Krege; Chia-Chi Lin; Noah Hahn; Thorsten H Ecke; Erin Moshier; Guru Sonpavde; James Godbold; William K Oh; Aristotle Bamias
Journal:  Urol Oncol       Date:  2013-02-18       Impact factor: 3.498

7.  [Geriatric assessment prior to oncological therapy].

Authors:  U Wedding
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

8.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

Authors: 
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

10.  Performance of two geriatric screening tools in older patients with cancer.

Authors:  Cindy Kenis; Lore Decoster; Katrien Van Puyvelde; Jacques De Grève; Godelieve Conings; Koen Milisen; Johan Flamaing; Jean-Pierre Lobelle; Hans Wildiers
Journal:  J Clin Oncol       Date:  2013-11-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.